Particle.news
Download on the App Store

Strides Sells Majority Stake in Pivot Path to Ascent-Led Consortium

The transaction gives Pivot Path fresh capital to operate as an independent, tech-focused pharma services firm.

Overview

  • Strides' board approved the deal on Saturday, June 27, under which a consortium led by Ascent Capital with co-investor Vintage Classic will acquire a majority stake in Pivot Path for an aggregate Rs 100 crore.
  • Ascent will put an additional Rs 50 crore of primary capital into Pivot Path and Strides will receive Rs 75 crore at closing with Rs 25 crore payable on the first anniversary.
  • The transaction sets a post-money valuation of Rs 230 crore and leaves Pivot Path with a post-transaction share split of 65.05% for investors, 19.95% for Strides, and a 15% ESOP pool for employees.
  • Pivot Path began inside Strides’ Arco Lab Global Capability Centre and now operates with more than 400 subject-matter experts in life‑sciences consulting, compliance, digital transformation and Agentic‑AI-enabled services.
  • Strides says the move unlocks value while keeping meaningful participation in Pivot Path’s future, and investors frame the deal as capital and strategic support to help the business scale global, technology-led compliance and drug‑safety services.